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Posttrial assessment of a vaccine’s selective pressure on infecting strains may be realized through a bioinformatic tool such
as parsimony phylogenetic analysis. Following a failed gonococcal pilus vaccine trial of Neisseria gonorrhoeae,w ec o n d u c t e da
phylogenetic analysis of pilin DNA and predicted peptide sequences from clinical isolates to assess the extent of the vaccine’s
eﬀect on the type of ﬁeld strains that the volunteers contracted. Ampliﬁed pilin DNA sequences from infected vaccinees, placebo
recipients, and vaccine specimens were phylogenetically analyzed. Cladograms show that the vaccine peptides have diverged
substantially from their paternal isolate by clustering distantly from each other. Pilin genes of the ﬁeld clinical isolates were
heterogeneous, and their peptides produced clades comprised of vaccinated and placebo recipients’ strains indicating that the
pilus vaccine did not exert any signiﬁcant selective pressure on gonorrhea ﬁeld strains. Furthermore, sequences of the semivariable
and hypervariable regions pointed out heterotachous rates of mutation and substitution.
1.Introduction
The recent failure of the HIV vaccine’s STEP Study is a
reminder that there is not usually an apparent reason that
may explain a trial’s demise [1, 2]. Only basic research will
provide an understanding of why a vaccine had not worked
andguidanceforthedesignofbettercandidates[2].Asastep
in this direction, we sought to provide a bioinformatic tool
that is capable of gauging whether a vaccine has exerted any
selectivepressureoninfectiousﬁeldstrains,asthismayaidin
reformulating the vaccine or the design of other candidates.
A comparative algorithmic model for establishing the extent
of a vaccines’ eﬃcacy is currently lacking although it may
contribute to the improvement of formulation and imple-
mentation of future vaccine hypotheses.
We are presenting a new analytical model that applies
the principles of phylogenetics, such as parsimony, to assess
whether a vaccine has aﬀected the selection of infectious
strains during a trial. Our approach relies on the robust
parsimonious modeling of fast arising genetic variation
to discriminate between two groups that are under dif-
ferent selective pressures [3, 4]. If a vaccine is shown
to exert a selective pressure, then its formulation can be
modiﬁed to broaden its eﬀective range. Although phyloge-
netic algorithms have been applied in the classiﬁcation of
microorganisms and to detect recombination in a multiple
sequence alignment, they have not been used in vaccine trial
assessment [5, 6].
This studyisafollowuponaﬁeldtrial conductedamong
U.S. personnel stationed in the Republic of South Korea [7].
For the trial, a puriﬁed pilus preparation was isolated from
Pgh 3-2 Neisseria gonorrhoeae strain and tested as a vaccine
in 3123 men and 127 women volunteers [7, 8]. Among
male volunteers, 108 vaccine and 102 placebo recipients
contracted gonorrhea after 15 or more days following vacci-
nation.Noneofthewomenvolunteersdevelopedgonococcal
infections. Samples of clinical isolates from all infected
participants were plated on selected media, identiﬁed, and
stored at the Department of Bacterial Diseases (Walter Reed
Army Institute of Research, Washington, DC, USA). The2 Advances in Bioinformatics
authors of the trial concluded that the pilus vaccine failed
to protect men against gonococcal urethritis during the ﬁeld
trial [7].
Gonococcal type IV pilus is ﬁlamentous proteinaceous
surface structure responsible for initial bacterial attachment
and is associated with virulence of N. gonorrhoeae (the
gonococcus) [9, 10]. The pilus is a polymer comprised
of pilin subunits; the latter share a common distinctive
structure that also occurs in the pilins of other genera
and is termed T4 pilin. The T4 pilin of N. gonorrhoeae is
comprised of a highly conserved domain (C: 1–53 amino
acids), a semivariable domain (SV: 54–114 amino acids), a
hypervariable region (HV: variable number of amino acids)
ﬂanked by two conserved regions with each containing a
cysteine residue, and a variable COOH-terminal region of
irregular length following the second cysteine region [11].
Genetic variation that occurs at the SV and HV regions
of the pilin involves a multigene system and has antigenic
implications [12, 13]. Within a gonococcal genome, a
structural gene (pilE) encodes for the pilin subunits. In
addition to pilE, the genome contains several silent pilin
genes (pilS); each pilS has one or more incomplete pilin
gene(s) arranged in tandem and connected by intervening
sequences [14]. Partial pilin copies of pilS lack the conserved
region of pilE but have the same arrangement of SV and
HV[14].Recombinationeventsbetweensilentandexpressed
sitesresultinvariationsintheexpressedpilin[15].Thus,pilE
replaces some, but not all, of its variable sites from any of the
silent copies.
The most suitable method for analyzing fast arising
mutations, such as those in the SV and HV regions of the
pilin, is sequencing followed by a parsimony phylogenetic
analysis [3]. Our analysis examines the pilin composition of
the vaccine and several clinical isolates from the vaccine trial
to assess whether the vaccine had any selective eﬀect on ﬁeld
strains that infected the vaccinated participants in spite of
its failure to protect participant from infection. We applied a
maximum parsimony phylogenetic algorithm to classify the
pilin sequences according to their phyletic relatedness [3, 4],
which has the capability to model a fast changing DNA and
recent divergence of genes better than maximum likelihood
or clustering [3].
2.MaterialsandMethods
2.1. Vaccine Strains and Clinical Isolates. Bacterial strains
from the vaccine trial were obtained from the depository
of the Department of Bacterial Diseases at Walter Reed
Army Institute of Research, Washington, DC, where they
were kept at −80◦C[ 7]. To our knowledge, the vaccine
strain did not undergo any further passages since vaccine
preparation and this study. All the isolates used in this work
were chosen randomly from positive samples; 40 isolates
coded from 1 to 40 were used for hybridization analysis, and
12 strains (Table 1) were used for the sequencing of their
pilin gene. Although the number of trial strains included in
the sequencing and phylogenetic analysis was restricted to 12
strains, it was still suﬃcient to test our hypothesis.
Table 1: Strains of Neisseria gonorrhoeae used in the study.
Strains Origin GenBank
Accessions
Pgh 3-2 clinical isolate [8] EU379154
P32 derived from Pgh 3-2 [7] EU379152
P32brntn vaccine strain derived from
Pgh 3-2 EU379153
P32brntn18 vaccine strain derived from
Pgh 3-2 U16742
68 from a vaccinated
participant EU340030
1009 from a vaccinated
participant EU360770
2132 from a vaccinated
participant EU379148
2184 from a vaccinated
participant EU379150
2968 from a vaccinated
participant EU379151
446 from a placebo recipient EU346893
854 from a placebo recipient EU360769
2136 from a placebo recipient EU379149
2.2. Pilin Gene Ampliﬁcation. Bacteria cells from the frozen
stock were used without subculture and lysed by heating
in 100µL of 5% Chilex (Bio-Rad, Hercules, CA) for 5 min
at 95◦C. For PCR, 5µL of the Chilex solution was used.
Primer selection was based on published sequences of pilin
genes [16, 17]; forward (TACATTGCATGATGCCGATGG)
and reverse (CGTTCCGCCCGCCCCAGCAGGC) primers
ampliﬁed only the expressed pilin gene (pilE) and not the
silent homologous copies.
2.3. Hybridization Experiments. To detect whether the
expressed pilin genes from the isolated ﬁeld strains were
homologous or heterologous to that of the vaccine strain,
P32brntn, the strains’ amplicons were probed with oligonu-
cleotides corresponding to the semivariable (SV) segments
and the hypervariable (HV) regions of the vaccine pilin.
Based on the pilin sequences of P32brntn, oligonucleotides
corresponding to variable segments of the SV (GCTTTC-
AAAAATCAT and CAAATGGCTTCAAGCAA) and the
total lengths of the HV (CCGACAACGACGACGTCAAA
and GAGGCCGCCAACAACGGC) were synthesized and
labeled with S35 isotope. Pilin gene amplicons from the 40
t r i a li s o l a t e sw e r ed o w n l o a d e do nan y l o nm e m b r a n ea n d
probed with the synthetic oligonucleotides. The hybridiza-
tions were carried out at diﬀerent stringency levels (50, 46,
and 42◦C) to detect the presence of closely homologous
sequences and the degree of heterogeneity within the ﬁeld
strains.
2.4. Amplicons Cloning, Sequencing, and Translation. The
PCR-produced amplicons of pilin gene from 12 strains
(Table 1) were cloned into an M13 vector (Applied Biosys-
tems, Foster City, CA). The cloned pilin genes wereAdvances in Bioinformatics 3
sequenced and translated into their predicted amino acids
using GeneDoc [18].
2.5. Parsimony Phylogenetic Analysis. We used Protpars from
thePHYLIPpackagetocarryouttheparsimonyphylogenetic
analysis [19]. Three sets of parsimony analyses, using amino
acid sequences, were carried out: ﬁrst, the whole sequence
of the gene; second, SV regions alone (amino acids 51–
127); and third, HV regions alone (amino acids 109–166).
The latter two regions were analyzed to ﬁnd out whether
their sequences produced similar results to that of the
whole sequence and whether the two regions’ phylogenies
were congruent with each other. This provided a test for
the strain-speciﬁc pilin hypothesis since diﬀerent regions
of the peptides should not produce substantially varying
hypotheses of relationships if the pilin is strain speciﬁc.
3. Results
First, the variability of the pilE gene in 40 clinical isolates was
analyzed by hybridization with the selected oligonucleotide
probes of the vaccine strain, P32brntn. The results were
negative at all stringency levels. This indicated the absence
of homologous or partially homologous pilin genes in the
clinical isolates of infected participants.
To conﬁrm this result, the sequencing analysis was
performed for the 12 samples presented in Table 1, including
the vaccine strain. We found that the vaccine strain con-
tained two pilin gene sequences (P32brntn and P32brntn18,
Table 1, Figure 1) instead of one pilin gene sequence as it was




congruent with the published structure of Neisseria pilins
(GenBank accessionnumbers are listed in Table 1). However,
the SV and HV regions (DNA and peptide sequences) of
ﬁeldstrainsweredissimilartothoseofthevaccine(Figure 1).
The variation among the sequences is shown phenetically
(i.e., overall similarity, Figure 1), and phylogenetically (their
phyletic relatedness, Figures 2–4).
Maximum parsimony analysis with Protpars [19] using
whole peptide sequences produced one parsimonious clado-
gram (Figure 2). The SVs produced 4 equally parsimonious
cladograms (Figure 3 shows the consensus cladogram);
the HVs produced 12 equally parsimonious cladograms
(Figure 4 shows the consensus cladogram).
Allthreeparsimonyphylogeneticanalysesdidnotassem-
ble separate groups for the strains isolated from vaccinees
cohort and those isolated from placebo recipients. The
strains of both groups were very closely related. This suggests
that the vaccine had no immunological selective pressure on
the isolates.
4. Discussion
Postvaccine trial analysis beyond success or failure is a rarity
due to lack of analytical methods. We are not aware of
any existing models for carrying out such an analysis. As
the HIV vaccine STEP Study has shown, a vaccine failure
sometimes is an enigma and no obvious reasons are at hand
to explain its failure [1, 2]. However, we are attempting here
tointroduceparsimonyphylogeneticanalysisasananalytical
paradigm for posttrial examination (it may also be used
for the formulation of future vaccine candidates). There are
several goals of such analysis: ﬁrst, to assess the heterogeneity
of ﬁeld strains in relation to vaccine strains; second, to
evaluate the phyletic relationships among all the strains; and
third, to ﬁnd out if the vaccine exerts any immunological
selectivepressureatthegeneleveloftheﬁeldstrainsthatmay
aﬀect the type of infecting strain.
The pilin gene sequence was not known at the time of
the vaccine trial, and attempts to sequence the pilus peptide’s
subunits were not completely successful. Our sequencing
results from the stored P32brntn strain revealed two distinct
pilE genes indicating that the culture has some heterogeneity
(P32brntn and P32brntn18, Table 1, Figure 1), which is in
contrast with the assumption of the vaccine trial authors of
a single-type pilus [7]. The exact composition of the vaccine
is signiﬁcant (whether it was a single-type or multiple-type
pilus) in order to assess its implications on the outcome of
the trial.
The eﬃcacy of a pilus vaccine in preventing gonorrhea
infections was the subject of a long debate fueled by
contradicting evidence [7, 20]. On one hand, the pili are
associated with gonorrhea’s virulence [21]; pilus vaccines
have been eﬀective in protecting suckling piglets and cattle
against infections of E. coli and Moraxella bovis,r e s p e c t i v e l y
[7, 22]; and these vaccines were immunogenic [23]. On
the other hand, the pilus vaccine was ineﬀective beyond
the homology of its pilus strain and even its homologous
protection was overcome with larger challenge inocula [20].
The authors of the vaccine trial argued that human challenge
experiments do not always predict the outcome in a natural
setting and embarked on a large placebo-controlled, double-
blinded ﬁeld trial of pilus vaccine [7]. Although the vaccine
elicited a good immune response in vaccinated recipients,
it failed to protect them [24]. This work examined the
extent of pilin diversity among infected participants and
pilinphylogenyasindicatorsofthevaccineselectivepressure.
We explored a new analytical model to determine whether
vaccine eﬀectiveness can be assessed on the basis of pilin
sequences phylogeny to infer whether the vaccine exerted a
selective pressure on the gonorrhea strains that infected the
vaccinated participants.
The heterogeneity of the vaccine inoculum (two pilin
types: P32brntn and P32brntn18) did not seem to confer
any additional eﬀectiveness on the vaccine. This could be
attributed to the close sequence similarity of the two; the two
typeshavesharedsequencesandgroupedtogetherinallthree
sets of the analyses (Figures 2–4).
In order to test the validity of our hypothesis, which
is based on the phylogeny of the pilin genes, the ancestral
strains, Pgh 3-2, a clinical isolate from which the vaccine
strain was derived [8], and a strain derived from it (P32),
were sequenced and included in the analyses. The two
ancestral strains clustered together in all three cladograms4 Advances in Bioinformatics
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Figure 1: Multiple sequence alignment of pilus predicted peptides from 12 strains used in the analysis (Table 1). These peptide sequences
were produced from translating DNA sequences (see Table 1 for GenBank accession numbers). There are three domains in the pilus peptide:
conserved domain (C: 1–53 amino acids), a semivariable domain (SV: 54–114 amino acids), and a hypervariable region (HV: variable
number of amino acids starting at amino acid 132). The color shadings (white, gray, and black) indicate the variability of the sequence; we













Figure 2: Most parsimonious cladogram of full-length predicted
peptides. Pgh 3-2 was used as an outgroup since it is the ancestral
strain of the vaccine strains. Strains from infected vaccinees are
marked by ∗. For a few strains, small sequence segments at the
beginningofthegenewerenotobtainedandweretreatedasmissing













Figure 3: Consensus cladogram of the semivariable (SV) regions
peptides (included amino acids 51–127). Pgh 3-2 was used as an
outgroup. Strains from vaccinated individuals are marked by ∗.
(Figures 2–4), while the vaccine pilins clustered distantly
from them. On two of the cladograms, the ancestral pilin
and the vaccine pilins were separated from each other by
all the other isolates (Figures 2 and 3). The vaccine pilins
consistently paired with the participants’ sequences. Since
the phylogenetic history of these strains is well known to













Figure 4: Consensus cladogram of the hypervariable (HV) regions
peptides (included amino acids 109–166). Pgh 3-2 was used as an
outgroup. Strains from vaccinated individuals are marked by ∗.
have diverged from their ancestral strains to a point where
their true phylogeny is not reﬂected in their pilin sequences.
Furthermore, it seems that because of recombination events
as well as high mutation rate, particularly at the HV region,
a strain-speciﬁc pilin appears to be an inaccurate term.
The phylogenetic analysis seems to indicate that the
vaccine did not appear to have inﬂuenced the strain type in
the vaccinated group. This is inferred from the groupings of
the sequences of the placebo and vaccinated groups where
they appear together in mixed groups (Figures 2–4). If the
vaccine had any selective pressure against gonorrhea strains,
the placebo and vaccinees groups would have been expected
to group separately from one another on the cladograms.
This study provided a clear insight into the magnitude
of antigenic variation of pilin exhibited among ﬁeld strains,
and therefore, permits an evaluation of the feasibility of pili
as a vaccine against one of the highest reported infections
in the US—gonorrhea [25]. This high heterogeneity of
pilin provides a strong reasoning against a single-type pilus
vaccine and lends support for multitype pilus of future
vaccine candidates.
Variation within the expressed pilin gene is partially
derived from intragenomic recombination events between
the former and copies of silent pilin genes pilS [26]. There-
fore, in light of the results obtained from phylogenetically
assessing the three segments of pilin gene (Figures 2–4), it
willbeimportanttoassessthedegreetowhichsilentcopiesin
the clinical isolates have contributed to the variation within
expressed pilin gene. This step is postponed for a future
study.
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